Doxa AB (publ) (DOXA.ST)
SEK 0.36
(1.14%)
SEK 0.36
(1.14%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 9.9 Million SEK | 8.15% |
| 2022 | -35.6 Million SEK | -550.63% |
| 2021 | 7.9 Million SEK | -5.92% |
| 2020 | 8.39 Million SEK | -25.34% |
| 2019 | 11.24 Million SEK | -62.72% |
| 2018 | 30.16 Million SEK | 115.49% |
| 2017 | 14 Million SEK | -12.92% |
| 2016 | 16.07 Million SEK | 51.09% |
| 2015 | 10.64 Million SEK | 65.0% |
| 2014 | 6.44 Million SEK | 106.1% |
| 2013 | 3.12 Million SEK | 312.86% |
| 2012 | -1.47 Million SEK | 81.65% |
| 2011 | -8.01 Million SEK | -1652.71% |
| 2010 | 516 Thousand SEK | 1964.0% |
| 2009 | 25 Thousand SEK | 400.0% |
| 2008 | 5000.00 SEK | -99.73% |
| 2007 | 1.82 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -5.9 Million SEK | 188.46% |
| 2024 Q1 | -5.2 Million SEK | -15.56% |
| 2023 Q1 | -9.4 Million SEK | 25.98% |
| 2023 FY | -32.7 Million SEK | 8.15% |
| 2023 Q2 | -27 Million SEK | -187.23% |
| 2023 Q4 | -4.5 Million SEK | -7.14% |
| 2023 Q3 | -4.2 Million SEK | 84.44% |
| 2022 Q1 | -14 Million SEK | 30.35% |
| 2022 FY | -35.6 Million SEK | -550.63% |
| 2022 Q4 | -12.7 Million SEK | -176.09% |
| 2022 Q3 | -4.6 Million SEK | -6.98% |
| 2022 Q2 | -4.3 Million SEK | 69.29% |
| 2021 FY | 7.9 Million SEK | -5.92% |
| 2021 Q2 | 2.6 Million SEK | -13.33% |
| 2021 Q3 | 1.8 Million SEK | -30.77% |
| 2021 Q4 | -20.1 Million SEK | -1216.67% |
| 2021 Q1 | 3 Million SEK | 20.14% |
| 2020 Q1 | 3.3 Million SEK | -46.32% |
| 2020 Q3 | 1.1 Million SEK | -9.09% |
| 2020 Q2 | 1.21 Million SEK | -63.33% |
| 2020 Q4 | 2.49 Million SEK | 127.0% |
| 2020 FY | 8.39 Million SEK | -25.34% |
| 2019 Q4 | 6.14 Million SEK | 379.41% |
| 2019 FY | 11.24 Million SEK | -62.72% |
| 2019 Q3 | -2.2 Million SEK | -157.89% |
| 2019 Q2 | 3.8 Million SEK | 8.57% |
| 2019 Q1 | 3.5 Million SEK | -11.79% |
| 2018 FY | 30.16 Million SEK | 115.49% |
| 2018 Q4 | 3.96 Million SEK | 13.37% |
| 2018 Q3 | 3.5 Million SEK | -82.76% |
| 2018 Q1 | 2.6 Million SEK | -39.53% |
| 2018 Q2 | 20.3 Million SEK | 680.77% |
| 2017 FY | 14 Million SEK | -12.92% |
| 2017 Q3 | 2.8 Million SEK | -9.68% |
| 2017 Q2 | 3.1 Million SEK | -3.13% |
| 2017 Q1 | 3.2 Million SEK | -49.02% |
| 2017 Q4 | 4.3 Million SEK | 53.57% |
| 2016 Q3 | 3.2 Million SEK | -15.79% |
| 2016 Q2 | 3.8 Million SEK | 35.71% |
| 2016 Q4 | 6.27 Million SEK | 96.16% |
| 2016 FY | 16.07 Million SEK | 51.09% |
| 2016 Q1 | 2.8 Million SEK | 6.02% |
| 2015 FY | 10.64 Million SEK | 65.0% |
| 2015 Q4 | 2.64 Million SEK | 1.58% |
| 2015 Q3 | 2.6 Million SEK | -16.13% |
| 2015 Q2 | 3.1 Million SEK | 34.78% |
| 2015 Q1 | 2.3 Million SEK | 48.48% |
| 2014 Q3 | 2 Million SEK | 17.65% |
| 2014 Q1 | 1.2 Million SEK | 10.6% |
| 2014 Q2 | 1.7 Million SEK | 41.67% |
| 2014 Q4 | 1.54 Million SEK | -22.55% |
| 2014 FY | 6.44 Million SEK | 106.1% |
| 2013 Q4 | 1.08 Million SEK | 35.63% |
| 2013 Q1 | 400 Thousand SEK | 131.62% |
| 2013 FY | 3.12 Million SEK | 312.86% |
| 2013 Q3 | 800 Thousand SEK | -11.11% |
| 2013 Q2 | 900 Thousand SEK | 125.0% |
| 2012 Q4 | -1.26 Million SEK | 0.0% |
| 2012 FY | -1.47 Million SEK | 81.65% |
| 2011 FY | -8.01 Million SEK | -1652.71% |
| 2010 FY | 516 Thousand SEK | 1964.0% |
| 2009 FY | 25 Thousand SEK | 400.0% |
| 2008 FY | 5000.00 SEK | -99.73% |
| 2007 FY | 1.82 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AddLife AB (publ) | 2.77 Billion SEK | 99.643% |
| Biotage AB (publ) | 1.14 Billion SEK | 99.138% |
| Bonesupport Holding AB (publ) | 533.12 Million SEK | 98.143% |
| Elekta AB (publ) | 6.77 Billion SEK | 99.854% |
| iZafe Group AB (publ) | 293 Thousand SEK | -3278.84% |
| Ortivus AB (publ) | 30.84 Million SEK | 67.9% |
| Ortivus AB (publ) | 30.84 Million SEK | 67.9% |
| Q-linea AB (publ) | 995 Thousand SEK | -894.975% |
| S2Medical AB (publ) | 5.03 Million SEK | -96.546% |
| Synsam AB (publ) | 617 Million SEK | 98.395% |